

DRAFT

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

Srivichaivejvivat Public Company Limited
and its subsidiaries
Review report and consolidated and separate financial
information
For the three-month period ended 31 March 2026

DRAFT

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Srivichaivejvivat Public Company Limited

I have reviewed the accompanying consolidated financial information of Srivichaivejvivat Public Company Limited and its subsidiaries, which comprises the consolidated statements of financial position as at 31 March 2026, the related consolidated statements of comprehensive income, of changes in shareholders' equity and cash flows for the three-month period then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Srivichaivejvivat Public Company Limited for the same period (collectively "the interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of Review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards as applicable to auditing issued by the Federation of Accounting Professions and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*.

Termphong Opanaphan

Certified Public Accountant (Thailand) No. 4501

EY Office Limited

Bangkok: 15 May 2026

Srivichaivejvivat Public Company Limited and its subsidiaries

Statements of financial position

As at 31 March 2026

DRAFT

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

		<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	<u>Note</u>	<u>31 March 2026</u>	<u>31 December 2025</u>	<u>31 March 2026</u>	<u>31 December 2025</u>
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Assets					
Current assets					
Cash and cash equivalents		818,471	807,291	173,360	227,553
Trade and other current receivables	3	623,627	635,142	217,034	234,613
Current portion of lease receivables		-	-	379	375
Medicine and supplies		72,518	57,492	26,015	19,162
Other current financial assets		681,361	570,127	444,880	333,646
Other current assets		14,539	9,894	6,009	3,299
Total current assets		2,210,516	2,079,946	867,677	818,648
Non-current assets					
Restricted bank deposits		410	410	-	-
Lease receivables, net of current portion		-	-	9,954	10,051
Other non-current financial assets		52,488	52,488	52,488	52,488
Investments in subsidiaries		-	-	1,058,433	1,058,433
Investment properties		-	-	33,095	33,095
Property, plant and equipment		2,258,058	2,264,515	1,103,199	1,107,615
Right-of-use assets		35,585	34,578	-	-
Deferred tax assets		20,567	19,963	-	-
Other non-current assets		19,864	24,611	12,602	14,109
Total non-current assets		2,386,972	2,396,565	2,269,771	2,275,791
Total assets		4,597,488	4,476,511	3,137,448	3,094,439

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

Srivichaivejvivat Public Company Limited and its subsidiaries

Statements of financial position (continued)

As at 31 March 2026

DRAFT

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	<u>31 March 2026</u>	<u>31 December 2025</u>	<u>31 March 2026</u>	<u>31 December 2025</u>
	(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and shareholders' equity				
Current liabilities				
Trade and other current payables	394,848	392,380	176,594	175,670
Current portion of lease liabilities	9,793	9,085	-	-
Income tax payable	58,088	41,973	20,811	15,484
Other current liabilities	4,837	4,623	1,412	1,525
Total current liabilities	467,566	448,061	198,817	192,679
Non-current liabilities				
Lease liabilities, net of current portion	58,390	58,388	-	-
Non-current provision for employee benefits	91,956	89,772	26,385	25,706
Deferred tax liabilities	464	638	435	607
Total non-current liabilities	150,810	148,798	26,820	26,313
Total liabilities	618,376	596,859	225,637	218,992

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

Srivichaivejvivat Public Company Limited and its subsidiaries

Statements of financial position (continued)

As at 31 March 2026

DRAFT

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		31 March 2026	31 December 2025	31 March 2026	31 December 2025
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Shareholders' equity					
Share capital	4				
Registered					
627,731,979 ordinary shares of Baht 1 each		627,732	627,732	627,732	627,732
Issued and fully paid					
618,646,732 ordinary shares of Baht 1 each					
(31 December 2025: 608,774,132 ordinary shares of Baht 1 each)		618,647	608,774	618,647	608,774
Share premium	4	372,484	303,376	372,484	303,376
Treasury shares	5	(2,787)	(2,787)	(2,787)	(2,787)
Advance received from share subscription	4	-	78,981	-	78,981
Retained earnings					
Appropriated - statutory reserve		62,773	62,773	62,773	62,773
Appropriated - treasury share reserve	5	2,787	2,787	2,787	2,787
Unappropriated		2,891,200	2,792,052	1,848,317	1,811,953
Other components of shareholders' equity		28,260	28,260	9,590	9,590
Equity attributable to owners of the Company		3,973,364	3,874,216	2,911,811	2,875,447
Non-controlling interests of the subsidiaries		5,748	5,436	-	-
Total shareholders' equity		3,979,112	3,879,652	2,911,811	2,875,447
Total liabilities and shareholders' equity		4,597,488	4,476,511	3,137,448	3,094,439

The accompanying notes are an integral part of the financial statements.

Directors

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

(Unaudited but reviewed)

DRAFT*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.***Srivichaivejvivat Public Company Limited and its subsidiaries****Statements of comprehensive income****For the three-month period ended 31 March 2026**

(Unit: Thousand Baht, except earnings per share expressed in Baht)

		Consolidated financial statements		Separate financial statements	
	Note	2026	2025	2026	2025
Profit or loss:					
Revenues					
Revenues from hospital operations		737,883	700,046	279,591	275,015
Dividend income		-	-	-	198,975
Other income		6,274	11,057	2,932	4,904
Total revenues		<u>744,157</u>	<u>711,103</u>	<u>282,523</u>	<u>478,894</u>
Expenses					
Cost of hospital operations		533,818	510,852	202,663	200,687
Selling expenses		16,916	20,720	6,160	6,095
Administrative expenses		67,981	57,567	28,275	18,418
Total expenses		<u>618,715</u>	<u>589,139</u>	<u>237,098</u>	<u>225,200</u>
Operating profit		<u>125,442</u>	<u>121,964</u>	<u>45,425</u>	<u>253,694</u>
Finance cost		(1,032)	(1,377)	-	(339)
Profit before income tax expenses		<u>124,410</u>	<u>120,587</u>	<u>45,425</u>	<u>253,355</u>
Income tax expenses		(24,950)	(21,741)	(9,061)	(8,578)
Profit for the period		<u>99,460</u>	<u>98,846</u>	<u>36,364</u>	<u>244,777</u>
Other comprehensive income for the period					
		-	-	-	-
Total comprehensive income for the period		<u>99,460</u>	<u>98,846</u>	<u>36,364</u>	<u>244,777</u>
Profit attributable to:					
Equity holders of the Company		99,148	98,586	<u>36,364</u>	<u>244,777</u>
Non-controlling interests of the subsidiaries		312	260		
		<u>99,460</u>	<u>98,846</u>		
Total comprehensive income attributable to:					
Equity holders of the Company		99,148	98,586	<u>36,364</u>	<u>244,777</u>
Non-controlling interests of the subsidiaries		312	260		
		<u>99,460</u>	<u>98,846</u>		
Earnings per share (Baht)					
	6				
Basic earnings per share					
Profit attributable to equity holders of the Company		<u>0.1606</u>	<u>0.1619</u>	<u>0.0589</u>	<u>0.4021</u>
Diluted earnings per share					
Profit attributable to equity holders of the Company		<u>0.1604</u>	<u>0.1619</u>	<u>0.0588</u>	<u>0.4021</u>

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Srivichaivejvivat Public Company Limited and its subsidiaries

Statements of changes in shareholders' equity

For the three-month period ended 31 March 2026

DRAFT
This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

Consolidated financial statements														
Equity attributable to owners of the Company														
								Other components of shareholders' equity						
								Other changes by the owners		Other comprehensive				
										Difference resulting from business combination under common control	Change in parent's ownership interest in subsidiaries without change in control	income Gain on investment in equity designated at fair value	Total other components of shareholders' equity	Total equity attributable to owners of the Company
Issued and paid-up share capital	Share premium	Treasury shares	Advance received from share subscription	Appropriated - statutory reserve	Appropriated - treasury share reserve	Unappropriated								
Balance as at 1 January 2025	608,710	302,926	-	514	62,773	-	2,510,847	37,531	(18,861)	9,461	28,131	3,513,901	5,996	3,519,897
Profit for the period	-	-	-	-	-	-	98,586	-	-	-	-	98,586	260	98,846
Other comprehensive income for the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	-	98,586	-	-	-	-	98,586	260	98,846
Issue ordinary shares as a result of warrants exercised (Note 4)	64	450	-	(514)	-	-	-	-	-	-	-	-	-	-
Dividend paid	-	-	-	-	-	-	-	-	-	-	-	-	(1,009)	(1,009)
Balance as at 31 March 2025	608,774	303,376	-	-	62,773	-	2,609,433	37,531	(18,861)	9,461	28,131	3,612,487	5,247	3,617,734
Balance as at 1 January 2026	608,774	303,376	(2,787)	78,981	62,773	2,787	2,792,052	37,531	(18,861)	9,590	28,260	3,874,216	5,436	3,879,652
Profit for the period	-	-	-	-	-	-	99,148	-	-	-	-	99,148	312	99,460
Other comprehensive income for the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	-	99,148	-	-	-	-	99,148	312	99,460
Issue ordinary shares as a result of warrants exercised (Note 4)	9,873	69,108	-	(78,981)	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2026	618,647	372,484	(2,787)	-	62,773	2,787	2,891,200	37,531	(18,861)	9,590	28,260	3,973,364	5,748	3,979,112

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

(Unaudited but reviewed)

Srivichaivejvivat Public Company Limited and its subsidiaries

Statements of changes in shareholders' equity (continued)

For the three-month period ended 31 March 2026

DRAFT

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

Separate financial statements

								Other components of shareholders' equity	
								Other comprehensive income	Total
	Issued and paid-up share capital	Share premium	Treasury shares	Advance received from share subscription	Appropriated - statutory reserve	Retained earnings Appropriated - treasury share reserve	Unappropriated	Gain on investment in equity designated at fair value	shareholders' equity
Balance as at 1 January 2025	608,710	302,926	-	514	62,773	-	1,420,677	9,461	2,405,061
Profit for the period	-	-	-	-	-	-	244,777	-	244,777
Other comprehensive income for the period	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	-	244,777	-	244,777
Issue ordinary shares as a result of warrants exercised (Note 4)	64	450	-	(514)	-	-	-	-	-
Balance as at 31 March 2025	<u>608,774</u>	<u>303,376</u>	<u>-</u>	<u>-</u>	<u>62,773</u>	<u>-</u>	<u>1,665,454</u>	<u>9,461</u>	<u>2,649,838</u>
Balance as at 1 January 2026	608,774	303,376	(2,787)	78,981	62,773	2,787	1,811,953	9,590	2,875,447
Profit for the period	-	-	-	-	-	-	36,364	-	36,364
Other comprehensive income for the period	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	-	36,364	-	36,364
Issue ordinary shares as a result of warrants exercised (Note 4)	9,873	69,108	-	(78,981)	-	-	-	-	-
Balance as at 31 March 2026	<u>618,647</u>	<u>372,484</u>	<u>(2,787)</u>	<u>-</u>	<u>62,773</u>	<u>2,787</u>	<u>1,848,317</u>	<u>9,590</u>	<u>2,911,811</u>

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

(Unaudited but reviewed)

DRAFT*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.***Srivichaivejvivat Public Company Limited and its subsidiaries****Cash flow statements****For the three-month period ended 31 March 2026**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
Cash flows from operating activities				
Profit before tax	124,410	120,587	45,425	253,355
Adjustments to reconcile profit before tax to net cash provided by (paid from) operating activities:				
Depreciation and amortisation	47,063	44,664	21,958	20,725
Allowance for expected credit losses	1,447	2,590	46	458
Reduction of medicine and supplies to net realisable value	94	77	56	41
Gain on disposals of equipment	(120)	(38)	-	(113)
Loss on write-off of equipment	386	73	68	13
Non-current provision for employee benefits	2,184	2,143	679	653
Dividend income	-	-	-	(198,975)
Interest income	(2,665)	(3,568)	(1,376)	(535)
Finance cost	1,032	1,377	-	339
Profit from operating activities before changes in operating assets and liabilities	173,831	167,905	66,856	75,961
Operating assets (increase) decrease				
Trade and other current receivables	11,240	14,663	17,962	1,032
Medicine and supplies	(15,120)	(1,458)	(6,909)	(763)
Other current assets	(4,645)	(2,473)	(2,710)	(981)
Other non-current assets	2,416	(1,213)	167	31
Operating liabilities increase (decrease)				
Trade and other current payables	6,575	(32,537)	(1,851)	(17,075)
Other current liabilities	214	(12,863)	(113)	(13,029)
Cash flows from operating activities	174,511	132,024	73,402	45,176
Interest received	925	2,776	131	170
Cash paid for corporate income tax and withholding tax deducted at source	(9,613)	(8,743)	(3,906)	(3,335)
Net cash from operating activities	165,823	126,057	69,627	42,011

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

(Unaudited but reviewed)

Srivichaivejvivat Public Company Limited and its subsidiaries**Cash flow statements (continued)****For the three-month period ended 31 March 2026**

DRAFT
This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
Cash flows from investing activities				
Increase of investment in other current financial assets	(111,234)	(226,394)	(111,234)	-
Cash received from lease receivables	-	-	217	216
Decrease of restricted bank deposits	-	98	-	-
Acquisition of buildings improvement and equipment	(14,413)	(25,827)	(8,849)	(8,780)
Cash paid for payable of buildings improvement and equipment	(25,948)	(25,545)	(4,481)	(2,769)
Acquisition of intangible assets	(161)	(781)	(161)	-
Cash receipt from dividend of subsidiaries	-	-	-	99,422
Proceeds from sales of equipment	120	42	-	250
Advance for purchase of equipment	(34)	(4,099)	-	-
Cash paid for payable from purchase of investment	-	(6,161)	-	(6,161)
Interest paid	-	(339)	-	(339)
Cash receipt from Interest	568	5	692	77
Net cash from (used in) investing activities	(151,102)	(289,001)	(123,816)	81,916
Cash flows from financing activities				
Payment of principal portion of lease liabilities	(2,505)	(2,082)	-	(28)
Interest paid	(1,032)	(1,037)	-	-
Dividend paid	(4)	(3)	(4)	(3)
Dividend paid to non-controlling interests of the subsidiaries	-	(573)	-	-
Net cash used in financing activities	(3,541)	(3,695)	(4)	(31)
Net increase (decrease) in cash and cash equivalents	11,180	(166,639)	(54,193)	123,896
Cash and cash equivalents at beginning of period	807,291	1,041,910	227,553	130,103
Cash and cash equivalents at end of period	818,471	875,271	173,360	253,999

Supplemental cash flows information

Non-cash items consist of:

Acquisition of buildings improvement and equipment

for which no cash has been paid

21,845	10,004	7,260	2,525
--------	--------	-------	-------

Transfer of advances for purchase of fixed assets

to property, plant and equipment

1,292	429	525	70
-------	-----	-----	----

Additions to right-of-use assets and lease liabilities

3,215	3,826	-	-
-------	-------	---	---

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

Srivichaivejvivat Public Company Limited and its subsidiaries
Condensed notes to interim financial statements
For the three-month period ended 31 March 2026

DRAFT

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

1. General information

1.1 Basis for the preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, with the Company presenting condensed interim financial statements. The Company has presented the statements of financial position, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements and has presented notes to the interim financial statements on a condensed basis.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language financial statements.

1.2 Basis of consolidation

The interim consolidated financial statements have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2025, with no change in shareholding structure of the Company and its subsidiaries during the current period.

1.3 Accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 December 2025.

The revised financial reporting standards which are effective for fiscal years beginning on or after 1 January 2026, do not have any significant impact on the Company and its subsidiaries' financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

DRAFT*This document is in draft form. It is subject to change and should not be relied upon as being accurate.***2. Related party transactions**

During the periods, the Company and its subsidiaries had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon between the Company and its subsidiaries and those related parties. There were no significant changes in the pricing policy of transactions with related parties.

Summaries significant business transactions with related parties as follows.

(Unit: Million Baht)

For the three-month periods ended 31 March

	Consolidated financial statements		Separate financial statements	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
<u>Transactions with subsidiaries</u>				
(eliminated from the consolidated financial statements)				
Medical service income	-	-	2	3
Dividend income	-	-	-	199
Medical service expenses	-	-	4	9

The balances of the accounts between the Company, its subsidiaries and those related parties are as follows:

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2026	2025	2026	2025
	(Audited)		(Audited)	
<u>Trade and other current receivables - related parties</u>				
(Note 3)				
Subsidiaries	-	-	3,491	3,024
Related company	357	359	-	-
Total trade and other current receivables				
- related parties	357	359	3,491	3,024
<u>Trade and other current payables - related parties</u>				
Subsidiaries	-	-	7,606	7,879
Related company and individuals	29	19	-	-
Total trade and other current payables				
- related parties	29	19	7,606	7,879

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

(Unaudited but reviewed)

DRAFT

This document is in draft form. It is subject to change and should not be relied upon as being accurate.

Directors and management's benefits

During the periods, the Company and its subsidiaries had employee benefit expenses payable to their directors and management as below.

(Unit: Thousand Baht)

	For the three-month periods ended 31 March			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
Short-term employee benefits	10,452	10,059	5,403	5,649
Post-employment benefits	203	172	62	36
Total	<u>10,655</u>	<u>10,231</u>	<u>5,465</u>	<u>5,685</u>

3. Trade and other current receivables

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
	(Audited)		(Audited)	
<u>Trade receivables - related parties</u>				
Aged on the basis of due dates				
Not yet due	-	-	975	975
Past due				
Up to 3 months	-	-	550	593
3 - 6 months	-	-	523	877
6 - 12 months	-	-	1,439	839
Over 12 months	-	-	522	258
Total	-	-	4,009	3,542
Less: Allowance for expected credit losses	-	-	(518)	(518)
Total trade receivables - related parties, net	-	-	3,491	3,024

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

(Unaudited but reviewed)

DRAFT

(Unit: Thousand Baht)

This document is in draft form. It is subject to review and change and its contents cannot be relied upon as being accurate.

Consolidated

financial statements

Separate

financial statements

	31 March 2026	31 December 2025	31 March 2026	31 December 2025
		(Audited)		(Audited)
<u>Trade receivables - unrelated parties</u>				
Aged on the basis of due dates				
Not yet due	308,184	312,500	75,571	76,272
Past due				
Up to 3 months	79,483	88,055	24,003	30,905
3 - 6 months	32,079	21,260	7,916	5,239
6 - 12 months	6,685	8,233	514	448
Over 12 months	6,397	1,928	644	642
Total	432,828	431,976	108,648	113,506
Less: Allowance for expected credit losses	(1,969)	(1,841)	(688)	(642)
Total trade receivables - unrelated parties, net	430,859	430,135	107,960	112,864
Total trade receivables - net	430,859	430,135	111,451	115,888
<u>Other current receivables - related parties</u>				
Other current receivables	357	359	-	-
Total other current receivables - related parties	357	359	-	-
<u>Other current receivables - unrelated parties</u>				
Other current receivables	4,461	4,581	2,374	3,351
Accrued income				
Accrued social security income	168,966	140,543	99,397	80,447
Other accrued income	25,259	64,480	3,812	34,927
Total	198,686	209,604	105,583	118,725
Less: Allowance for expected credit losses	(6,275)	(4,956)	-	-
Total other current receivables				
- unrelated parties, net	192,411	204,648	105,583	118,725
Total other current receivables - net	192,768	205,007	105,583	118,725
Total trade and other current receivables - net	623,627	635,142	217,034	234,613

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

DRAFT

This document is in draft form. It is subject to change and should not be relied upon as being accurate.

4. Warrants and share capital

On 30 December 2025, holders of the warrants to purchase ordinary shares of the Company No. 1 (VIH-W1) exercised 9,872,591 units to purchase 9,872,591 newly issued ordinary shares with a par value of Baht 1 each, at an exercise price of Baht 8 per share. The Company recorded a total of Baht 78,980,728 received from the exercise of rights as a separate item in the statement of financial position as at 31 December 2025 under the account "Advance received from share subscription".

The Company registered the increase in its issued and paid-up share capital with the Ministry of Commerce on 9 January 2026.

During the three-month period ended 31 March 2026, no exercise of the Company's warrants to purchase ordinary shares.

As at 31 March 2026, a total of 9,085,210 units of the warrants to purchase ordinary shares of the Company No. 1 (VIH-W1) remained unexercised.

5. Treasury shares

On 28 February 2025, a meeting of the Company's Board of Directors No.2/2025 passed a resolution approving the share repurchase program for financial management. The Company will repurchase its ordinary shares through the Stock Exchange of Thailand between 17 March 2025 to 16 September 2025 and will resell them after 3 months but not later than 3 years after the completion date of the share repurchase program.

As of the end of the repurchase period, the Company repurchased 404,700 million shares under the share repurchase program, equivalent to 0.07% of its issued and paid-up capital, at an average price of Baht 6.89 resulting in a total cost of Baht 2.79 million. At the same time, the Company has allocated retained earnings as a reserve for the same amount of treasury shares.

6. Earnings per share

Basic earnings per share is calculated by dividing profit for the period attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issued during the period, net of treasury shares held by the Company.

Diluted earnings per share is calculated by dividing profit for the period attributable to equity holder of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the period, net of treasury shares held by the Company plus the weighted average number of ordinary shares which would need to be issued to convert warrants into ordinary shares. The calculation assumes that the conversion took place either at the beginning of the period or on the date the potential ordinary shares were issued. However, the Company has not presented the diluted earnings per share for the three-month period ended 31 March 2025 since the average market price of ordinary share is lower than the exercise price of the warrants.

I, the undersigned, hereby approve these financial statements and notes thereto, and hereby approve their issue in final form.

.....
Directors

(Unaudited but reviewed)

The following table sets forth the computation of basic and diluted earnings per share:

DRAFT

This document is in draft form. It is subject to review and change and therefore its content cannot be relied upon as being accurate.

(Unit: Thousand Shares)

	Consolidated/Separate financial statements	
	For the three-month periods ended 31 March	
	<u>2026</u>	<u>2025</u>
Number of ordinary shares issued and paid-up	608,774	608,709
Increase share capital issue ordinary shares as a result of warrants	8,995	60
Effect of treasury share	(405)	-
Weighted average number of ordinary shares	<u>617,364</u>	<u>608,769</u>

	For the three-month periods ended 31 March					
	Consolidated financial statements				Earnings	
	Profit for the period		Weighted average number of ordinary shares		per share	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
	(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share						
Profit attributable to equity holders of the parent	99,148	98,586	617,364	608,769	0.1606	0.1619
Effect of dilutive potential ordinary shares						
Warrant VIH-W1	-	-	680	-		
Diluted earnings per share						
Profit attributable to ordinary shareholders assuming the conversion of warrants to ordinary shares	<u>99,148</u>	<u>98,586</u>	<u>618,044</u>	<u>608,769</u>	<u>0.1604</u>	<u>0.1619</u>

	For the three-month periods ended 31 March					
	Separate financial statements				Earnings	
	Profit for the period		Weighted average number of ordinary shares		per share	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
	(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share						
Profit attributable to equity holders of the parent	36,364	244,777	617,364	608,769	0.0589	0.4021
Effect of dilutive potential ordinary shares						
Warrant VIH-W1	-	-	680	-		
Diluted earnings per share						
Profit attributable to ordinary shareholders assuming the conversion of warrants to ordinary shares	<u>36,364</u>	<u>244,777</u>	<u>618,044</u>	<u>608,769</u>	<u>0.0588</u>	<u>0.4021</u>

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

DRAFT*This document is in draft form. It is subject to change. Any reference to it cannot be relied upon as being accurate.***7. Segment information**

The Company and its subsidiaries are principally engaged in the hospital business. A subsidiary is engaged in operating a vocational school, but the revenue from which is immaterial. The Company and its subsidiaries operate in a single geographic area in Thailand. Therefore, revenues, operating profit and total assets presented in the financial statements relate to the said principal business and location.

8. Commitments and contingent liabilities**8.1 Capital commitments**

As at 31 March 2026 and 31 December 2025, the Company and its subsidiaries had capital commitments as follows:

	(Unit: Million Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2026	2025	2026	2025
		(Audited)		(Audited)
Construction of buildings and the buildings improvement	34.8	42.8	1.9	6.9
Acquisition of medical devices and hospital equipment	5.3	13.0	2.4	4.8
Others	0.6	0.2	0.1	-

8.2 Service commitments

The Company and its subsidiaries have entered into consulting, cleaning services provider, security services provider, medical equipment maintenance service, and other service agreements with related individuals and unrelated parties.

As at 31 March 2026, future minimum payments required under those service contracts were contracting to Baht 31 million (31 December 2025: Baht 37 million) (the Company only: Baht 11 million, 31 December 2025: Baht 14 million).

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors

DRAFT*This document is in draft form. It is subject to change and its contents should not be relied upon as being accurate.***8.3 Guarantees**

There were outstanding bank guarantees issued by banks on behalf of the Company and its subsidiaries in respect of certain performance bonds as required in the normal course of business as follows:

	(Unit: Million Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2026	2025	2026	2025
		(Audited)		(Audited)
Bank guarantees for the medical treatment service contracts with the Social Security Office	23.3	47.7	13.6	27.1
Bank guarantees for the medical treatment service contracts with the National Health Security Office	1.4	1.4	0.2	0.2
Bank guarantees for electricity use	4.4	4.4	1.8	1.8
Bank guarantees for service contracts	1.0	4.5	-	-
Bank guarantees for bidding of health check-up service contracts	9.2	16.7	-	-

9. Events after the reporting period

On 24 April 2026, the Annual General Meeting of the Company's shareholders for the year 2026 passed the resolution approving the payment of dividend for 2025 of Baht 0.40 per share, totaling Baht 247.30 million. The Company will pay such dividend on 22 May 2026.

10. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 15 May 2026.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....
Directors